S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
52-week Low Names To Tip The Upside Scale In Your Favor
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Is New IPO Instacart Already Hitting Speed Bumps?
Prospect Capital Corporation: A Gold Nugget or Value Trap?
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Analysts Went All In On These Computer Stocks, Save Your Spot
Seagen, Activision Blizzard rise; Scholastic, Intel fall, Friday, 9/22/2023
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
52-week Low Names To Tip The Upside Scale In Your Favor
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Is New IPO Instacart Already Hitting Speed Bumps?
Prospect Capital Corporation: A Gold Nugget or Value Trap?
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Analysts Went All In On These Computer Stocks, Save Your Spot
Seagen, Activision Blizzard rise; Scholastic, Intel fall, Friday, 9/22/2023
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
52-week Low Names To Tip The Upside Scale In Your Favor
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Is New IPO Instacart Already Hitting Speed Bumps?
Prospect Capital Corporation: A Gold Nugget or Value Trap?
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Analysts Went All In On These Computer Stocks, Save Your Spot
Seagen, Activision Blizzard rise; Scholastic, Intel fall, Friday, 9/22/2023
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
52-week Low Names To Tip The Upside Scale In Your Favor
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Is New IPO Instacart Already Hitting Speed Bumps?
Prospect Capital Corporation: A Gold Nugget or Value Trap?
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Analysts Went All In On These Computer Stocks, Save Your Spot
Seagen, Activision Blizzard rise; Scholastic, Intel fall, Friday, 9/22/2023
NASDAQ:ATOS

Atossa Therapeutics (ATOS) Stock Forecast, Price & News

$0.83
+0.04 (+5.06%)
(As of 09/22/2023 ET)
Compare
Today's Range
$0.78
$0.84
50-Day Range
$0.74
$1.20
52-Week Range
$0.50
$1.39
Volume
553,452 shs
Average Volume
612,960 shs
Market Capitalization
$104.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.50

Atossa Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
562.7% Upside
$5.50 Price Target
Short Interest
Bearish
6.52% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-1.05mentions of Atossa Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.27) to ($0.28) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.65 out of 5 stars

Medical Sector

858th out of 966 stocks

Pharmaceutical Preparations Industry

411th out of 449 stocks


ATOS stock logo

About Atossa Therapeutics (NASDAQ:ATOS) Stock

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201 for lung injury caused by cancer treatment. In addition, the company develops immunotherapy/chimeric antigen receptor therapy programs. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

ATOS Price History

ATOS Stock News Headlines

The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
Reverse ‘money machines’ popping up across America
If you’ve been to a concert venue, stadium, or airport, you’ve almost certainly walked by one without knowing. The experts are calling it a 'Reverse ATM' Why are these machines suddenly appearing out of nowhere? And what does it mean for your money?
Q2 2023 Atossa Therapeutics Inc Earnings Call
Maxim Group Keeps Their Buy Rating on Atossa Therapeutics (ATOS)
Maxim upbeat on Atossa Therapeutics after recent updates
See More Headlines
Receive ATOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Atossa Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ATOS Company Calendar

Last Earnings
8/14/2023
Today
9/22/2023
Next Earnings (Estimated)
11/06/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ATOS
Employees
11
Year Founded
2009

Price Target and Rating

Average Stock Price Forecast
$5.50
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+562.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-26,960,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.93 per share

Miscellaneous

Free Float
115,974,000
Market Cap
$104.41 million
Optionable
Not Optionable
Beta
1.28

Social Links

10 Best Stocks to Own in 2023 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Steven C. Quay FCAP (Age 72)
    M.D., Ph.D., Chairman, CEO & Pres
    Comp: $1.14M
  • Mr. Gregory L. Weaver CPAMr. Gregory L. Weaver CPA (Age 67)
    M.B.A., CFO & Director
    Comp: $80k
  • Ms. Heather Rees
    VP of Fin. & Accounting
  • Ms. Delly Behen P.H.R.
    VP of Admin. & HR
  • Mr. Eric Van Zanten
    VP of Investor & PR
  • Dr. Richard Graydon M.D.
    Ph.D., Interim Chief Medical Officer













ATOS Stock - Frequently Asked Questions

Should I buy or sell Atossa Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Atossa Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ATOS shares.
View ATOS analyst ratings
or view top-rated stocks.

What is Atossa Therapeutics' stock price forecast for 2023?

1 brokers have issued 1-year price objectives for Atossa Therapeutics' shares. Their ATOS share price forecasts range from $5.00 to $6.00. On average, they predict the company's stock price to reach $5.50 in the next year. This suggests a possible upside of 562.7% from the stock's current price.
View analysts price targets for ATOS
or view top-rated stocks among Wall Street analysts.

How have ATOS shares performed in 2023?

Atossa Therapeutics' stock was trading at $0.5285 on January 1st, 2023. Since then, ATOS stock has increased by 57.0% and is now trading at $0.83.
View the best growth stocks for 2023 here
.

When is Atossa Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our ATOS earnings forecast
.

How were Atossa Therapeutics' earnings last quarter?

Atossa Therapeutics, Inc. (NASDAQ:ATOS) released its quarterly earnings results on Monday, August, 14th. The company reported ($0.06) earnings per share for the quarter, meeting the consensus estimate of ($0.06).

When did Atossa Therapeutics' stock split?

Atossa Therapeutics shares reverse split before market open on Friday, April 20th 2018. The 1-12 reverse split was announced on Friday, April 20th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, April 19th 2018. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

What is Steven C. Quay's approval rating as Atossa Therapeutics' CEO?

8 employees have rated Atossa Therapeutics Chief Executive Officer Steven C. Quay on Glassdoor.com. Steven C. Quay has an approval rating of 53% among the company's employees. This puts Steven C. Quay in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 29.0% of employees surveyed would recommend working at Atossa Therapeutics to a friend.

What other stocks do shareholders of Atossa Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Atossa Therapeutics investors own include AVEO Pharmaceuticals (AVEO), Alibaba Group (BABA), Heat Biologics (HTBX), Vaxart (VXRT), Biocept (BIOC), MannKind (MNKD), Biopharmx (BPMX), Daré Bioscience (DARE), OPKO Health (OPK) and Nokia Oyj (NOK).

What is Atossa Therapeutics' stock symbol?

Atossa Therapeutics trades on the NASDAQ under the ticker symbol "ATOS."

Who are Atossa Therapeutics' major shareholders?

Atossa Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (2.29%), Geode Capital Management LLC (0.88%), Renaissance Technologies LLC (0.85%), State Street Corp (0.34%), Bank of New York Mellon Corp (0.09%) and Virtu Financial LLC (0.07%).
View institutional ownership trends
.

How do I buy shares of Atossa Therapeutics?

Shares of ATOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Atossa Therapeutics' stock price today?

One share of ATOS stock can currently be purchased for approximately $0.83.

How much money does Atossa Therapeutics make?

Atossa Therapeutics (NASDAQ:ATOS) has a market capitalization of $104.41 million. The company earns $-26,960,000.00 in net income (profit) each year or ($0.25) on an earnings per share basis.

How can I contact Atossa Therapeutics?

Atossa Therapeutics' mailing address is 107 SPRING STREET, SEATTLE WA, 98104. The official website for the company is atossatherapeutics.com. The company can be reached via phone at (206) 588-0256, via email at scottg@coreir.com, or via fax at 206-430-1288.

This page (NASDAQ:ATOS) was last updated on 9/23/2023 by MarketBeat.com Staff

My Account -